GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » Piotroski F-Score

Gamida Cell (Gamida Cell) Piotroski F-Score : 4 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gamida Cell has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Gamida Cell's Piotroski F-Score or its related term are showing as below:

GMDAQ' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 4
Current: 4

During the past 8 years, the highest Piotroski F-Score of Gamida Cell was 4. The lowest was 1. And the median was 2.


Gamida Cell Piotroski F-Score Historical Data

The historical data trend for Gamida Cell's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gamida Cell Piotroski F-Score Chart

Gamida Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 1.00 3.00 2.00 2.00 4.00

Gamida Cell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 2.00 3.00 4.00

Competitive Comparison of Gamida Cell's Piotroski F-Score

For the Biotechnology subindustry, Gamida Cell's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gamida Cell's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gamida Cell's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gamida Cell's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -20.96 + -31.676 + -1.519 + -8.841 = $-63.00 Mil.
Cash Flow from Operations was -22.284 + -22.003 + -18.57 + -16.263 = $-79.12 Mil.
Revenue was 0 + 0 + 0.673 + 1.111 = $1.78 Mil.
Gross Profit was 0 + 0 + 0.047 + -3.798 = $-3.75 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(124.773 + 105.132 + 112.508 + 117.748 + 102.186) / 5 = $112.4694 Mil.
Total Assets at the begining of this year (Dec22) was $124.77 Mil.
Long-Term Debt & Capital Lease Obligation was $75.17 Mil.
Total Current Assets was $54.55 Mil.
Total Current Liabilities was $25.20 Mil.
Net Income was -20.223 + -18.554 + -17.802 + -22.796 = $-79.38 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(148.786 + 124.538 + 108.021 + 114.312 + 124.773) / 5 = $124.086 Mil.
Total Assets at the begining of last year (Dec21) was $148.79 Mil.
Long-Term Debt & Capital Lease Obligation was $101.32 Mil.
Total Current Assets was $66.55 Mil.
Total Current Liabilities was $24.88 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gamida Cell's current Net Income (TTM) was -63.00. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gamida Cell's current Cash Flow from Operations (TTM) was -79.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-62.996/124.773
=-0.50488487

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-79.375/148.786
=-0.53348433

Gamida Cell's return on assets of this year was -0.50488487. Gamida Cell's return on assets of last year was -0.53348433. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gamida Cell's current Net Income (TTM) was -63.00. Gamida Cell's current Cash Flow from Operations (TTM) was -79.12. ==> -79.12 <= -63.00 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=75.168/112.4694
=0.66834179

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=101.317/124.086
=0.81650629

Gamida Cell's gearing of this year was 0.66834179. Gamida Cell's gearing of last year was 0.81650629. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=54.546/25.201
=2.16443792

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=66.546/24.875
=2.67521608

Gamida Cell's current ratio of this year was 2.16443792. Gamida Cell's current ratio of last year was 2.67521608. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gamida Cell's number of shares in issue this year was 135.758. Gamida Cell's number of shares in issue last year was 75.84. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-3.751/1.784
=-2.10257848

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Gamida Cell's gross margin of this year was -2.10257848. Gamida Cell's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1.784/124.773
=0.01429797

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/148.786
=0

Gamida Cell's asset turnover of this year was 0.01429797. Gamida Cell's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gamida Cell has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Gamida Cell  (OTCPK:GMDAQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gamida Cell Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Gamida Cell's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gamida Cell (Gamida Cell) Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
Jeremy Blank director 6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho officer: Chief Financial Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov officer: CMO & Chief Scientific Officer 1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins director, officer: President and CEO C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov director C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd. other: Affiliate of 10% Owner 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry officer: Chief Financial Officer C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc other: Affiliate of 10% Owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd. other: Affiliate of 10% Owner 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Gamida Cell (Gamida Cell) Headlines

From GuruFocus

Q3 2020 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q2 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell BLA Acceptance Call Transcript

By GuruFocus Research 02-07-2024

Q1 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Investor Day Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024